Lipoproteins are spherical particles composed of a hydrophobic lipid core and a hydrophilic surface shell. The core is enriched in hydrophobic lipids such as cholesteryl esters and triglycerides, whereas the surface is formed by phospholipids, free cholesterol, and apolipoproteins, enabling efficient packaging, storage, transport, and metabolic allocation of hydrophobic lipids in aqueous biofluids such as plasma. Dysregulated lipoprotein metabolism is often accompanied by system-wide shifts in both lipid and protein components and is associated with disease processes including atherosclerosis, diabetes, obesity, and cancer. Accordingly, lipoproteins are central to lipid-metabolism research and constitute a foundational platform for clinical biomarker systems, drug development, and bioengineering applications.
Keywords: lipoprotein; apolipoprotein; chylomicron; VLDL; IDL; LDL; HDL; lipoprotein(a); ELISA; methodological standardization
I. Core Concepts and Compositional Basis
1.1 Concept and Structural Essentials
(1) Basic definition
Lipoproteins are the primary carriers of insoluble lipids in blood and represent lipid–protein complexes. Their fundamental role is to transform hydrophobic lipids into stably dispersed transport units in aqueous environments and, through interactions with receptors and enzymatic systems, enable tissue distribution and metabolic clearance.
(2) Particle architecture
① Hydrophobic core: predominantly cholesteryl esters and triglycerides; determines the lipid cargo type and density characteristics.
② Hydrophilic shell: a phospholipid monolayer with free cholesterol at the interface; maintains structural stability in aqueous media.
③ Apolipoproteins: located on the particle surface; provide structural support and govern receptor recognition, enzymatic regulation, and metabolic fate.
1.2 Modes of Intermolecular Interaction
In lipoproteins, lipids and proteins are generally not linked by covalent bonds. Assembly is primarily driven by non-covalent forces, including hydrophobic interactions, electrostatic interactions, and interface energy minimization. This assembly logic confers component exchangeability and structural remodeling capacity. Therefore, research and applications should control compositional consistency, structural state, and modification status in parallel.
1.3 Functional Scope of Apolipoproteins
Beyond particle assembly and lipid transport, apolipoproteins also mediate:
(1) Receptor-ligand function: determines binding and uptake routes via receptors such as the LDL receptor family and SR-BI.
(2) Enzymatic regulation: modulates key nodes (e.g., LPL, LCAT, CETP), thereby shaping particle interconversion and lipid flux.
(3) Inflammation/immune coupling: in acute-phase responses or chronic inflammatory settings, remodeling of apolipoprotein profiles can alter cellular responses to lipoproteins and their pathological associations.
II. Physicochemical Properties, Identification Methods, and Classification Systems
2.1 Common Identification Criteria
(1) Chemical composition
Particle characteristics can be described by the proportions of triglycerides (TG), cholesterol/cholesteryl esters, phospholipids, and protein, supporting judgments about whether energy-lipid load or cholesterol load is dominant.
(2) Centrifugation sedimentation/flotation behavior
Density-gradient ultracentrifugation separates lipoprotein fractions by density, enabling acquisition of relatively purified CM, VLDL, LDL, HDL fractions for downstream functional studies.
(3) Electrophoretic mobility
Electrophoretic phenotyping reflects differences in surface charge and protein composition. It is suitable for rapid typing and abnormal-pattern alerts, and is best interpreted quantitatively when combined with density fractionation and multi-omics profiling.
2.2 Major Lipoprotein Classes by Density
(1) Chylomicrons (CM)
The largest particles with the lowest density, primarily transporting exogenous (diet-derived) triglycerides and fat-soluble nutrients. Blood collection and study design should stringently control fasting duration and sampling windows to avoid CM carryover that can confound interpretation.
(2) Very-low-density lipoproteins (VLDL)
Synthesized and secreted by the liver; TG-rich and responsible for endogenous triglyceride export. The efficiency of LPL-mediated hydrolysis largely determines remnant accumulation and the downstream IDL/LDL formation burden.
(3) Intermediate-density lipoproteins (IDL)
A transitional fraction in the VLDL-to-LDL conversion pathway. Its level relates to receptor-mediated clearance efficiency and can serve as an indicator of “conversion bottlenecks” and remnant burden.
(4) Low-density lipoproteins (LDL)
Relatively enriched in cholesteryl esters and deliver cholesterol to peripheral tissues. Risk association extends beyond LDL-C to include particle number, size distribution, and modification status; research often incorporates apoB, size spectra, or modification indices to strengthen mechanistic interpretation.
(5) High-density lipoproteins (HDL)
Protein-rich with the highest density; involved in reverse cholesterol transport and processes linked to antioxidant and anti-inflammatory activity. It is important to distinguish HDL-C concentration from HDL functionality (e.g., efflux capacity, antioxidant capacity) and avoid substituting concentration metrics for functional inference.
2.3 Complementary View: Electrophoretic Phenotypes
Electrophoresis can separate lipoproteins into migration bands such as chylomicrons, pre-β lipoproteins, β lipoproteins, and α lipoproteins, largely reflecting surface charge and protein-composition differences. This approach is suitable for screening and indicative analyses, whereas mechanistic studies benefit from pairing it with density fractionation and omics for higher resolution.
2.4 Special Subtype: Lipoprotein(a)
Lipoprotein(a) is primarily synthesized in the liver and is often regarded as an independent risk factor for atherosclerosis and thrombosis-related outcomes. Its research value includes:
(1) Residual-risk stratification: complements traditional LDL-related metrics.
(2) Genetically driven features: substantial inter-individual variability, supporting genotype–phenotype association studies.
(3) Mechanistic coupling directions: inferred links to inflammation and inhibition of fibrinolysis, requiring rigorous experimental and statistical validation.
III. Biological Functions and Disease Associations
3.1 Lipid Transport and Tissue Allocation
(1) Exogenous lipid transport
Chylomicrons transport dietary TG and fat-soluble nutrients; LPL-mediated hydrolysis releases fatty acids for tissue oxidation or storage.
(2) Endogenous lipid transport
VLDL exports liver-derived TG to provide energy substrates to peripheral tissues; its metabolic conversion shapes circulating remnant burden and LDL production.
(3) Cholesterol homeostasis
LDL delivers cholesterol to peripheral tissues. HDL promotes cholesterol return to the liver for metabolism or biliary excretion, forming a closed-loop homeostatic circuit.
3.2 Key Enzyme Systems and Receptor Interactions
(1) LPL-related pathways
LPL-driven TG hydrolysis is the decisive step for CM/VLDL conversion into remnants. Apolipoproteins and regulatory proteins modulate LPL efficiency, influencing TG clearance rates and remnant accumulation.
(2) LDL receptor pathway
LDL binding to LDL receptors followed by endocytosis constitutes the main route for circulating LDL clearance and cellular cholesterol uptake. Altered pathway efficiency affects both plasma LDL levels and intracellular cholesterol homeostasis.
(3) Lipid exchange and maturation mechanisms
Processes including LCAT-mediated esterification and lipid transfer remodel inter-lipoprotein lipid flow and particle maturation, thereby shaping HDL functionality and the global lipoprotein profile architecture.
3.3 Pathophysiological Axis: Atherosclerosis and Inflammation
(1) apoB-containing particle burden and intimal retention
apoB-containing lipoproteins can enter and be retained in the arterial intima, establishing a local particle-burden substrate.
(2) Modification and foam-cell formation
Oxidation, glycation, and other modifications enhance macrophage uptake and cholesterol deposition, promoting foam-cell formation and amplifying inflammatory responses.
(3) Metabolic dysregulation coupled to immune networks
States such as diabetes and obesity remodel lipoprotein profiles and apolipoprotein composition while altering oxidative stress and endothelial function, yielding systemic metabolic–immune coupling abnormalities.
3.4 Clinical Concept of Lipoprotein Disorders
Lipoprotein disorders provide a more comprehensive description of dysregulated lipid metabolism, encompassing hypercholesterolemia, hypertriglyceridemia, mixed dyslipidemia, and low HDL states. In research and translational settings, it is advisable to distinguish primary (genetic-driven) from secondary (metabolic/endocrine abnormalities; hepatobiliary and renal conditions; alcohol- or drug-related drivers) to align mechanistic aims with intervention evaluation.
IV. Methodologies for Measurement and Characterization
4.1 Routine Clinical Metrics and Extended Indicators
(1) Standard lipid panel
Total cholesterol, TG, LDL-C, and HDL-C reflect overall lipid "cargo load," but are not equivalent to particle number or function.
(2) Extended indicators
① apoB: more directly reflects apoB-containing particle burden; useful when LDL-C and risk are discordant.
② Lipoprotein(a): supports residual-risk stratification and genetic association studies.
③ HDL functional metrics: mechanistically clarify inconsistencies between HDL-C concentration and protective effects.
4.2 Fractionation and Particle Size/Density Analyses
(1) Density-gradient ultracentrifugation
Enables density-based fraction isolation for downstream composition assays, receptor binding/uptake experiments, and modification sensitivity analyses.
(2) Gel filtration / SEC strategies
Provide size distribution and aggregation information and support mapping between size spectra and functional readouts.
(3) NMR and spectroscopic approaches
Enable indirect estimation of size distributions and particle numbers, supporting high-throughput profiling in cohort studies.
4.3 Composition and Functional Assays
(1) Lipidomics and proteomics
Resolve lipid species and apolipoprotein profiles to identify structural bases of functional differences.
(2) Modification and oxidation sensitivity assessment
Measures oxidation levels and glycation-related modifications to explain differences in uptake, inflammation, and risk phenotypes.
(3) Cell-based functional experiments
Include cholesterol efflux, receptor binding/uptake, endothelial inflammatory responses, and macrophage foam-cell formation to translate structural characterization into mechanistic evidence.
V. Application Domains and Representative Scenarios
5.1 Clinical Testing and Risk Stratification
(1) Cardiometabolic risk assessment
LDL-C, non-HDL-C, apoB, and Lp(a) capture risk across "cargo load–particle burden–specific subtype" layers and support population stratification and intervention evaluation.
(2) Metabolic disease assessment
TG-rich lipoproteins correlate strongly with insulin resistance and fatty-liver phenotypes and can support metabolic sub-phenotyping and response evaluation.
5.2 Drug Discovery and Pharmacodynamic Evaluation
(1) Interventions targeting lipoprotein metabolic axes
Lipid-lowering and metabolic interventions often act by altering particle production, conversion, or clearance. Lipoprotein profiles, apoB, and Lp(a) support mechanistic validation and pharmacodynamic quantification.
(2) Inflammation–lipid coupling target exploration
Associations among lipoprotein modification, receptor recognition, and immune responses can motivate target hypotheses that are then cross-validated using cellular/animal models and population data.
5.3 Drug Delivery and Nanomedicine
(1) Leveraging intrinsic delivery properties
LDL and HDL have defined receptor-mediated interaction routes. Loading hydrophobic drugs, imaging probes, or nucleic-acid delivery units into native lipoproteins or biomimetic particles can:
① exploit receptor-mediated uptake to yield tissue/cell-type bias (e.g., liver; macrophage-enriched regions in the arterial wall; lipid-uptake pathways in certain tumor cells).
② improve aqueous dispersibility and stability of hydrophobic payloads, reducing non-specific aggregation and rapid clearance.
③ increase predictability and reproducibility of biodistribution while maintaining surface "identity cues" contributed by apolipoproteins.
(2) Biomimetic lipoprotein nanoparticles
Biomimetic designs typically emulate a "hydrophobic core–phospholipid shell–apolipoprotein presentation" architecture to increase encapsulation and enable controlled release. Key quality attributes should cover size distribution, aggregation propensity, apolipoprotein retention/substitution strategy, drug loading and encapsulation efficiency, oxidation status, and batch-to-batch consistency.
5.4 Biomaterials and In Vitro Models
(1) Standardized supplementation in in vitro models
Lipoproteins can simulate plasma lipid environments to study endothelial function, macrophage foam-cell formation, and smooth-muscle phenotype transitions. Experimental designs should specify lipoprotein source, modification status, and dosing basis (protein mass/cholesterol mass/particle number) and include matched controls.
(2) Colloid and interfacial science model system
As natural colloidal particles, lipoproteins enable studies of protein–lipid interfacial stability, self-assembly rules, and component-exchange kinetics, providing parameters for biomimetic carrier design.
5.5 Immunology and Microbiology Applications
(1) Immune activation and adjuvant design
Bacterial lipoproteins, via membrane anchoring and innate immune recognition features, can support pathway studies and candidate adjuvant evaluation.
(2) Diagnostic antigens and target screening
Membrane lipoprotein epitopes can be leveraged for serology or molecular diagnostic target development, requiring specificity and cross-reactivity assessments to define performance boundaries.
VI. Typical Experimental Use Cases for Lipoproteins in Research
6.1 Cellular Models: Uptake, Cholesterol Homeostasis, and Foam-Cell Formation
(1) LDL uptake and cholesterol-loading models
Used to interrogate LDL receptor pathways, cholesterol endocytosis, and intracellular accumulation. Typical readouts include intracellular cholesterol quantification, lipid-droplet accumulation, receptor expression, and downstream signaling changes.
(2) Modified LDL in foam-cell/inflammation mechanisms
Models how particle modification in the arterial-intima microenvironment enhances uptake and amplifies inflammation, enabling comparison of modification extent versus foam-cell and stress-pathway outputs.
(3) HDL/reconstituted HDL efflux assays
Used to study cholesterol efflux and reverse-transport pathways, typically using HDL or reconstituted HDL as acceptors and dissecting mechanisms via ABCA1/ABCG1 dependence, receptor blockade, or genetic perturbations.
6.2 Animal and Population Studies: Phenotype Stratification and Pharmacodynamic Readouts
(1) Phenotype stratification
Lipoprotein profiling helps define metabolic background and reduces confounding when interpreting intervention effects.
(2) Intervention evaluation
Profiles plus apoB and Lp(a) can quantify efficacy and help infer whether changes are driven by production, conversion, or clearance.
(3) Particle-burden–oriented design
When particle number, rather than cholesterol cargo, is the focus, apoB, size spectra, or NMR-derived particle counts provide stronger explanatory power and should be pre-specified as primary endpoints at the protocol stage.
6.3 Biomimetic Delivery and Nanoparticle Research
(1) Targeted uptake validation
Competition, blockade, and uptake-kinetic experiments can be performed, with tissue distribution or intracellular accumulation as validation readouts.
(2) Stability and exchange behavior assessment
Evaluate whether protein-corona remodeling, payload leakage, or oxidation shifts occur in serum environments to ensure comparability between in vitro and in vivo findings.
VII. Appropriate Use Cases for Lipoprotein-Related ELISA Kits
7.1 When Shifting from Lipid Cargo Load to Protein/Subtype Burden Quantification
(1) Apolipoprotein quantification
apoB reflects apoB-containing particle burden; apoA-I reflects the major structural protein of HDL and helps interpret discordance between LDL-C/HDL-C and phenotypes.
(2) Lipoprotein(a) quantification
Supports residual-risk stratification, genotype–phenotype research, and intervention-response evaluation.
(3) Modified lipoprotein quantification
For example, oxidized LDL (oxLDL) supports quantitative links between modification burden and inflammation, endothelial injury, or foam-cell phenotypes.
7.2 Sample Types and Applicable Settings
(1) Serum/plasma
Suitable for medium-to-high-throughput testing in cohort studies, animal interventions, and pharmacodynamic evaluations.
(2) Cell supernatants and culture systems
Suitable for assessing marker changes driven by uptake, secretion, or treatments; requires baseline medium controls and tight control of serum sources.
(3) Tissue homogenates
Suitable for local microenvironment studies; extraction conditions should be assessed for epitope integrity and validated via spike-recovery.
7.3 Technical Basis for Choosing ELISA
ELISA is well-suited for standardized quantification of protein components, specific subtypes, or modification epitopes, enabling high-throughput measurements, cross-batch comparability, and statistical inference.
VIII. Practical Considerations and Methodological Risk Control
8.1 Pre-analytical Variables: Sampling, Storage, and Oxidation State
(1) Sampling and processing timing
Delayed centrifugation or prolonged room-temperature exposure increases oxidation and component exchange, altering profiles and functional readouts. Standardize the time window from sampling to fractionation and lock operating procedures.
(2) Freeze–thaw cycle control
Repeated freeze–thaw can induce aggregation, protein exchange, and epitope alterations, compromising consistency in ELISA and functional assays. Aliquot and record freeze–thaw counts.
(3) Metal ions and light management
Metal contamination and light exposure promote oxidation, elevating oxLDL background or impairing HDL functionality. Use low-metal consumables and limit light exposure.
8.2 Matrix Interference and Consistency Control
(1) Serum vs plasma differences
Anticoagulant type can affect particle stability and certain assay systems. Fix the sample type and avoid direct cross-type comparisons.
(2) Hemolysis, lipemia, and icterus interference
These can influence colorimetric readouts and immunoassay background. Establish exclusion criteria or conduct sensitivity analyses and document handling in statistical workflows.
(3) Lipoprotein background in culture media
Serum-containing media introduce lipoproteins that confound treatment experiments and ELISA outputs. Consider delipidated serum, serum-free treatment windows, or well-defined supplementation systems; include medium blanks and matched protein controls.
8.3 Standardization of Lipoprotein Preparation and Handling
(1) Source and lot consistency
Naturally isolated lipoproteins exhibit inter-individual and batch variability. Record source, isolation method, purity metrics, and storage conditions; use the same lot for critical experiments when possible.
(2) Consistency of modified lipoproteins
Oxidation conditions, quenching strategies, and QC metrics (oxidation degree, size shifts, epitope retention) should be fixed; otherwise cellular phenotypes and immunoassay outputs are not comparable.
(3) Unified dosing basis
Specify whether dosing is based on cholesterol mass, protein mass (apoA-I/apoB), or particle number, and maintain the same basis throughout to avoid effect-size misinterpretation.
8.4 Methodological Control Points for ELISA
(1) Dilution linearity and spike-recovery
Validate dilution linearity and spike-recovery for key samples to confirm matrix effects are controlled and quantification is within a reliable range.
(2) Standard and matrix matching
Use dilution buffers and blocking conditions that closely match the sample matrix to reduce curve distortion in real samples.
(3) Antibody epitope differences and cross-reactivity
Different kits can define epitopes and cross-reactivity profiles differently for the same marker. Cross-kit or cross-lot comparisons require concordance assessment; reference materials may be needed for calibration.
IX. Aladdin-Related Products
Catalog No. | Product Name | Grade and Purity | Application Area |
Oxidized low density lipoprotein (Human) | ≥98% | Atherosclerosis and cardiovascular research | |
Lipoproteins, Low Density, Human Plasma | ≥95% | Lipid testing and lipoprotein profiling | |
Lipoproteins, High Density, Human Plasma | ≥95% | Reverse cholesterol transport and antioxidant research | |
Human Oxidized Low Density Lipoprotein (OX-LDL) from Human Plasma | BioReagent, Native | Atherosclerosis and OxLDL research | |
Low density lipoprotein (human) | -- | LDL-related disease research | |
Oxidized low density lipoprotein (mouse) | ≥98% | OxLDL-related disease research | |
Lipoproteins, Intermediate Density, Human Plasma | ≥95% | IDL metabolism research | |
Lipoproteins, Very Low Density, Human Plasma | ≥95% | Hepatic lipid metabolism research | |
Lipoproteins, High Density, Human Plasma, Suitable for Cell Culture | ≥95% | Cell models and lipoprotein function research | |
Lipoproteins, Low Density, Human Plasma, Suitable for Cell Culture | ≥95% | Cell culture and LDL function research | |
Lipoproteins, Very Low Density, Human Plasma, Suitable for Cell Culture | ≥95% | Cell culture and lipoprotein metabolism research | |
Rat Low Density LipoProtein (LDL) ELISA Kit | BioReagent | Rat lipid research | |
Rat High Density LipoProtein (HDL) ELISA Kit | BioReagent | Rat HDL research | |
Mouse Low Density LipoProtein (LDL) ELISA Kit | BioReagent | Mouse LDL research | |
Human High Density LipoProtein (HDL) ELISA Kit | BioReagent | Human HDL testing and reverse cholesterol transport research | |
Human Low Density LipoProtein (LDL) ELISA Kit | BioReagent | Human LDL testing and atherosclerosis research | |
Mouse High Density LipoProtein (HDL) ELISA Kit | BioReagent | Mouse HDL testing and lipid metabolism research | |
Rat High-density LipoProtein 3 (HDL3) ELISA Kit | BioReagent | Rat HDL3 research | |
Mouse High-density lipoProtein 3(HDL3) ELISA Kit | BioReagent | Mouse HDL3 research | |
Mouse High-density lipoProtein 2(HDL2) ELISA Kit | BioReagent | Mouse HDL2 research | |
Human Very Low Density LipoProtein (VLDL) ELISA Kit | BioReagent | Human VLDL research | |
Rat Oxidized Low Density LipoProtein (OxLDL) ELISA Kit | BioReagent | Rat OxLDL research | |
Mouse Oxidized Low Density LipoProtein (OxLDL) ELISA Kit | BioReagent | Mouse OxLDL research | |
Mouse Very Low Density LipoProtein (VLDL) ELISA Kit | BioReagent | Mouse VLDL research | |
Human High Density LipoProtein 2 (HDL2) ELISA Kit | BioReagent | Human HDL2 research | |
Human Oxidized Low Density LipoProtein (OxLDL) ELISA Kit | BioReagent | Human OxLDL testing | |
Rat Very Low Density LipoProtein (VLDL) ELISA Kit | BioReagent | Rat VLDL research |
By integrating a hydrophobic core, a hydrophilic shell, and apolipoprotein-mediated identity cues, lipoproteins enable lipid packaging, transport, and metabolic regulation in biofluids. Their dysregulation is closely linked to atherosclerosis, diabetes, obesity, and cancer. In research practice, lipoproteins support mechanistic models of uptake, foam-cell formation, and cholesterol efflux, and enable phenotype stratification and pharmacodynamic evaluation in animal and population studies. When standardized quantification of protein components, subtype burden, or modification status is required, lipoprotein-related ELISA kits provide throughput and comparability advantages. Systematic control of pre-analytical variables, matrix interference, material batch consistency, and immunoassay QC substantially improves reproducibility and mechanistic interpretability in lipoprotein research.